SCHEMBL490376

SCHEMBL490376

CC(C(=O)O)c1cc(O)c(O)cc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 7/20 0.51
PTGS1 P23219 5/20 0.51
GRM1 Q13255 1/20 0.42
FFAR1 O14842 2/20 0.39
LMNA P02545 4/20 0.38
KDM4E B2RXH2 3/20 0.38
RECQL P46063 3/20 0.38
MAPT P10636 3/20 0.38
USP2 O75604 2/20 0.38
CYP3A4 P08684 2/20 0.38
THPO P40225 2/20 0.38
HIF1A Q16665 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
PMP22 Q01453 2/20 0.38
CYP2C9 P11712 2/20 0.38
NFKB1 P19838 2/20 0.38
RGS12 O14924 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31402519 1.00 PTGS2 (0.51) PTGS2PTGS1GRM1FFAR1LMNA
SCHEMBL3833416 0.85 PTGS1 (0.47) PTGS2PTGS1GRM1LMNAKDM4E
SCHEMBL490490 0.77 TYR (0.55) PTGS2PTGS1MAPTCYP3A4ALDH1A1
SCHEMBL490883 0.77 PTGS2 (0.60) PTGS2PTGS1LMNAKDM4ERECQL
SCHEMBL29429345 0.77 TYR (0.55) PTGS2PTGS1MAPTCYP3A4ALDH1A1
SCHEMBL28955098 0.75 TYR (0.44) PTGS2PTGS1KDM4EMAPTCYP3A4
SCHEMBL28238190 0.75 TRPA1 (0.62) PTGS2PTGS1LMNAMAPTALDH1A1
SCHEMBL3833747 0.75 PTGS2 (0.42) PTGS2PTGS1GRM1FFAR1LMNA
SCHEMBL28487478 0.74 ALOX15 (0.46) PTGS2PTGS1GRM1LMNAKDM4E
SCHEMBL6591473 0.74 PTGS2 (0.57) PTGS2PTGS1LMNAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268293-B2 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2012-09-18 US disclosed
CN-101163659-B Antioxidants MERCK PATENT GMBH 2012-09-05 CN disclosed
US-8106233-B2 Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing MERCK PATENT GMBH (DE) 2012-01-31 US disclosed
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2008-07-17 US disclosed
US-20080152603-A1 Antioxidants SUSONITY Commercial GmbH (DE) 2008-06-26 US disclosed
CN-101163659-A Antioxidants MERCK PATENT GMBH (DE) 2008-04-16 CN disclosed
EP-1871339-A1 UV PROTECTION Merck Patent GmbH (DE) 2008-01-02 EP disclosed
EP-1871735-A1 ANTIOXIDANTS Merck Patent GmbH (DE) 2008-01-02 EP disclosed
WO-2006111233-A1 ANTIOXIDANTS MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed
WO-2006111234-A1 UV PROTECTION MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152603-A1 Antioxidants GPX4, GPX1, CAT PTGS2 320/4885PTGS1 262/4885GRM1 3880/4885
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives HPD, HAAO, UGT1A6 PTGS2 1873/4885PTGS1 1937/4885GRM1 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.